|MolMed S p A -- Germany Stock|| |
EUR 0.54 0.01 1.89%
Mr. Alfredo Messina serves as a NonExecutive Director of Molecular Medicine S.p.A. since November 6, 2007. He served as Controller of the production division of Olivetti and then moved to Alitalia as Central Director of the Administration, Finance and Control division. He was also Director of Planning and Control of IRI. He joined Fininvest in 1990, first as General Manager, then as Managing Director of Administration and Control. He serves as First Vice Chairman of Mediolanum SpA, Chairman of Mediolanum Assicurazioni, Mediolanum Vita and Vacanze Italia. He is also Member of the Board of Directors of Mediaset SpA and Gestevision Telecinco SA. He is Member of the Board of Directors of PI distribuzione SpA and Quinta Communications SA. He studied Business Economics.
Age: 81 Director Since 2007
39 02 21 27 71 http://www.molmed.com
The company has return on total asset (ROA)
of (18.1) %
which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (61.21) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. MolMed S.p.A. was founded in 1996 and is headquartered in Milan, Italy. MolMed S is traded on Frankfurt Stock Exchange in Germany.MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. It is located in Via Olgettina, 58 and employs 23 people.